Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.03SPGP 1ZUQ.TO 0.55NVDA 0.32GL 1.66MRK -1.71IEMG 0.5GEV 33.87
Daily Stock Opinions and Ratings
Stockchase Opinions

Richard StoneNovelionNVLN.TOBUY ON WEAKNESSDec 01, 2000

Client base may not be big enough for revenues needed. If you see a weak day, BUY
Richard StoneRichard Stone
Unknown
Unlock Rating
$74.30

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY ON WEAKNESS

Novelion(NVLN.TO)

Aug 07, 2009
(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
Photo of Benj GallanderBenj GallanderUnlock Rating
$4.10

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Novelion(NVLN.TO)

Oct 23, 2007
The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$4.35

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Dec 22, 2005
Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
Photo of Laura WallaceLaura Wallace
No
Unlock Rating
$7.04

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Novelion(NVLN.TO)

Nov 11, 2005
The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$8.10

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Sep 29, 2005
The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$9.00

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Aug 11, 2005
Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
Photo of Gordon Higgins, CA, MBAGordon Higgins, CA, MBA
No
Unlock Rating
$10.00

Stock price when the opinion was issued

biotechnologypharmaceutical
WAIT

Novelion(NVLN.TO)

Jun 15, 2005
Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
Photo of David CockfieldDavid Cockfield
Owned
Unlock Rating
$11.89

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Jun 06, 2005
A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$12.59

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Novelion(NVLN.TO)

May 25, 2005
Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$13.02

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Apr 11, 2005
This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$15.37

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Mar 10, 2005
Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.
Photo of David CockfieldDavid Cockfield
Owned
Unlock Rating
$15.63

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Novelion(NVLN.TO)

Mar 09, 2005
Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$15.36

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Feb 15, 2005
You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$18.81

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Feb 14, 2005
Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$18.24

Stock price when the opinion was issued

biotechnologypharmaceutical
WAIT

Novelion(NVLN.TO)

Feb 01, 2005
Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.
Photo of Mark Jackson, CFAMark Jackson, CFA
No
Unlock Rating
$19.94

Stock price when the opinion was issued

biotechnologypharmaceutical
The ultimate 360° Tracker Your financial life in one place, automatically

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.03$37.25
ET 0.31$19.07
MAIR 0$
RKLB -12.39$102.39
SESG-O 0$

Today's Top Picks

HMP.TO 0.03$9.75
SPGP 1$120.39
ZUQ.TO 0.55$107.47
NVDA 0.32$205.19
GL 1.66$166.76

Popular Articles

Latest Sell Signals

PRGO 0.09$10.99
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica